Cancer Genetics (NASDAQ:CGIX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cancer Genetics (NASDAQ:CGIX) in a research report sent to investors on Monday. The brokerage issued a sell rating on the stock.

Cancer Genetics Stock Performance

Shares of Cancer Genetics stock opened at $0.19 on Monday. The company has a 50 day moving average price of $0.17. Cancer Genetics has a 52-week low of $2.11 and a 52-week high of $17.50. The firm has a market cap of $765,896.65, a price-to-earnings ratio of -0.09 and a beta of 2.72.

Cancer Genetics Company Profile

Vyant Bio, Inc is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease.